Overview

This is a summary of the European public assessment report (EPAR) for Entacapone Teva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Entacapone Teva.

Entacapone Teva is a medicine that contains the active substance entacapone. It is available as tablets (200 mg).

Entacapone Teva is a ‘generic medicine’. This means that Entacapone Teva is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Comtess.

Entacapone Teva is used to treat patients with Parkinson’s disease. Parkinson’s disease is a progressive brain disorder that causes shaking, slow movement and muscle stiffness. Entacapone Teva is used together with levodopa (either a combination of levodopa and benserazide or a combination of levodopa and carbidopa) when the patient is having ‘fluctuations’ towards the end of the period between two doses of their medication. Fluctuations happen when the effects of the medication wear off and symptoms re-emerge. They are linked with a reduction in the effects of levodopa, when the patient experiences sudden switches between being ‘on’ and able to move, and being ‘off’ and having difficulties moving about. Entacapone Teva is used when these fluctuations cannot be treated with the standard levodopa-containing combination alone.

The medicine can only be obtained with a prescription.

Entacapone Teva is only used in combination either with levodopa and benserazide or with levodopa and carbidopa. It is taken as one tablet with each dose of the other medicine, up to a maximum of 10 tablets a day. When patients first add Entacapone Teva to their existing medication, they may need to take a lower daily dose of levodopa, either by changing how often they take it, or by reducing the amount of levodopa taken in each dose. Entacapone Teva can only be used with conventional combinations of levodopa. It should not be used with combinations that are ‘modified release’ (when the levodopa is released slowly over a few hours).

In patients with Parkinson’s disease, the cells in the brain that produce the neurotransmitter dopamine begin to die and the amount of dopamine in the brain decreases. The patients then lose their ability to control their movements reliably. The active substance in Entacapone Teva, entacapone, works to restore the levels of dopamine in the parts of the brain that control movement and coordination. It only works when it is taken with levodopa, a copy of the neurotransmitter dopamine that can be taken by mouth. Entacapone blocks an enzyme that is involved in the breakdown of levodopa in the body called catechol-O-methyl transferase (COMT). As a result, levodopa remains active for longer. This helps to improve the symptoms of Parkinson’s disease, such as stiffness and slowness of movement.

Because Entacapone Teva is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Comtess. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

Because Entacapone Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.

The CHMP concluded that, in accordance with EU requirements, Entacapone Teva has been shown to have comparable quality and to be bioequivalent to Comtess. Therefore, the CHMP’s view was that, as for Comtess, the benefit outweighs the identified risk. The Committee recommended that Entacapone Teva be given marketing authorisation.

The European Commission granted a marketing authorisation valid throughout the European Union for Entacapone Teva on 18 February 2011.

For more information about treatment with Entacapone Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Entacapone Teva : EPAR - Summary for the public

български (BG) (102.91 KB - PDF)
español (ES) (75.42 KB - PDF)
čeština (CS) (97.76 KB - PDF)
dansk (DA) (73.98 KB - PDF)
Deutsch (DE) (77.18 KB - PDF)
eesti keel (ET) (73.89 KB - PDF)
ελληνικά (EL) (104.2 KB - PDF)
français (FR) (76.44 KB - PDF)
hrvatski (HR) (90.1 KB - PDF)
italiano (IT) (75.45 KB - PDF)
latviešu valoda (LV) (100.82 KB - PDF)
lietuvių kalba (LT) (95.58 KB - PDF)
magyar (HU) (95.52 KB - PDF)
Malti (MT) (99.54 KB - PDF)
Nederlands (NL) (75.26 KB - PDF)
polski (PL) (100.47 KB - PDF)
português (PT) (78.12 KB - PDF)
română (RO) (96.99 KB - PDF)
slovenčina (SK) (97.88 KB - PDF)
slovenščina (SL) (89.25 KB - PDF)
Suomi (FI) (76.1 KB - PDF)
svenska (SV) (74.41 KB - PDF)

Product information

Entacapone Teva : EPAR - Product Information

български (BG) (415.99 KB - PDF)
español (ES) (339.15 KB - PDF)
čeština (CS) (355.58 KB - PDF)
dansk (DA) (327.7 KB - PDF)
Deutsch (DE) (357.25 KB - PDF)
eesti keel (ET) (352.24 KB - PDF)
ελληνικά (EL) (422.57 KB - PDF)
français (FR) (360.26 KB - PDF)
hrvatski (HR) (393.56 KB - PDF)
íslenska (IS) (342.23 KB - PDF)
italiano (IT) (358.13 KB - PDF)
latviešu valoda (LV) (384.74 KB - PDF)
lietuvių kalba (LT) (382.31 KB - PDF)
magyar (HU) (392.05 KB - PDF)
Malti (MT) (400.06 KB - PDF)
Nederlands (NL) (377.97 KB - PDF)
norsk (NO) (345.83 KB - PDF)
polski (PL) (383.98 KB - PDF)
português (PT) (375.91 KB - PDF)
română (RO) (376.7 KB - PDF)
slovenčina (SK) (411.01 KB - PDF)
slovenščina (SL) (366.91 KB - PDF)
Suomi (FI) (337.08 KB - PDF)
svenska (SV) (386.14 KB - PDF)

Latest procedure affecting product information: N/0018

10/09/2021

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Entacapone Teva : EPAR - All Authorised presentations

български (BG) (52.7 KB - PDF)
español (ES) (21.77 KB - PDF)
čeština (CS) (49.69 KB - PDF)
dansk (DA) (21.36 KB - PDF)
Deutsch (DE) (21.41 KB - PDF)
eesti keel (ET) (21.63 KB - PDF)
ελληνικά (EL) (52.17 KB - PDF)
français (FR) (21.59 KB - PDF)
hrvatski (HR) (26.95 KB - PDF)
íslenska (IS) (21.63 KB - PDF)
italiano (IT) (21.2 KB - PDF)
latviešu valoda (LV) (49.37 KB - PDF)
lietuvių kalba (LT) (49.93 KB - PDF)
magyar (HU) (50.69 KB - PDF)
Malti (MT) (49.95 KB - PDF)
Nederlands (NL) (21.16 KB - PDF)
norsk (NO) (25.32 KB - PDF)
polski (PL) (35.23 KB - PDF)
português (PT) (21.73 KB - PDF)
română (RO) (49.42 KB - PDF)
slovenčina (SK) (49.98 KB - PDF)
slovenščina (SL) (36.62 KB - PDF)
Suomi (FI) (21.4 KB - PDF)
svenska (SV) (21.52 KB - PDF)

Product details

Name of medicine
Entacapone Teva
Active substance
entacapone
International non-proprietary name (INN) or common name
entacapone
Therapeutic area (MeSH)
Parkinson Disease
Anatomical therapeutic chemical (ATC) code
N04BX02

Pharmacotherapeutic group

Anti-Parkinson drugs

Therapeutic indication

Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.

Authorisation details

EMA product number
EMEA/H/C/002075

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Marketing authorisation holder
Teva Pharma B.V.

Computerweg 10
NL-3542 DR Utrecht
The Netherlands

Opinion adopted
18/11/2010
Marketing authorisation issued
18/02/2011
Revision
10

Assessment history

Entacapone Teva : EPAR - Procedural steps taken and scientific information after authorisation

Entacapone Teva : EPAR - Public assessment report

CHMP summary of positive opinion for Entacapone Teva

This page was last updated on

How useful do you find this page?